Gilead Sciences Inc. executives enthusiastically advocated for the company's $11.9bn acquisition Kite Pharma Inc. on Aug. 28, but investors had mixed feelings about the $180-per-share price tag, despite overwhelmingly positive efficacy for Kite's lead chimeric antigen receptor T cell (CAR-T) therapy to date.
What's Gilead Getting From Kite For Nearly $12bn?
The $180 per share that Gilead's paying for CAR-T maker Kite was deemed too high by some and just right by others, but the big biotech expects a lot from its new cell therapy platform.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.